How Medtech Trends Are Reshaping North American Manufacturing and Trade

Executive Summary

The medical technology (medtech) industry is entering a period of accelerated transformation. Global pricing reforms, shifting care delivery models, supply chain volatility, and the emergence of AI-enabled platforms are redefining how devices are developed, manufactured, and commercialized. For North America—a region that remains a critical hub for medtech innovation and production—these trends carry significant implications for cross-border trade, industrial policy, and long-term competitiveness.

This article distills five key trends identified in Clarivate’s Medtech Trends to Watch 2026 report and examines their relevance to North American manufacturing and trade. While the original analysis focuses on global market dynamics, the following assessment highlights how these forces are reshaping supply chains, investment decisions, and regional integration under the USMCA.

Introduction

The medtech sector has long been a bright spot in North American manufacturing, with the United States serving as the world’s largest market and Mexico emerging as a key production hub. However, the industry now faces a convergence of pressures: China’s expanding volume-based procurement (VBP) program is resetting global price expectations; U.S. policy shifts are accelerating the migration of procedures to outpatient settings; tariffs and geopolitical tensions are forcing supply chain realignment; and digital health technologies are creating new competitive dynamics.

These trends are not isolated. They interlock to influence corporate strategy, factory location decisions, and trade flows across the United States, Canada, and Mexico. For policymakers and business leaders, understanding these dynamics is essential to maintaining North America’s edge in medtech innovation and manufacturing.

Main Analysis

1. China’s VBP Expansion Reshapes Global Pricing and Market Access

China’s national volume-based procurement program has evolved from a cost-containment tool into a structural force in global medtech pricing. The latest rounds introduce more sophisticated anchor-pricing mechanisms, deeper price cuts, and allocation systems that favor domestic manufacturers. For multinational companies with significant North American operations, VBP is no longer a localized issue; it influences portfolio strategies, R&D priorities, and pricing benchmarks in other emerging markets.

Why it matters for North America: As price pressure mounts in China, medtech companies are increasingly looking to North America for revenue stability. This reinforces the region’s importance as a high-value market and encourages investment in advanced manufacturing capabilities that can support premium product lines. At the same time, the competitive threat from Chinese device makers could intensify in export markets, pressuring North American firms to differentiate through innovation and quality.

2. Outpatient Care Expansion Reframes Demand and Manufacturing Mix

The continued shift of procedures from hospitals to ambulatory surgical centers (ASCs) and outpatient facilities is altering device requirements. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 payment rules have further expanded the ASC Covered Procedure List, including higher-acuity cardiac interventions. This trend is part of a broader movement toward value-based care that prioritizes cost efficiency and shorter recovery times.

Why it matters for North America: Device manufacturers must adapt product designs, sterilization methods, and packaging for the ASC setting. This may favor nimble supply chains and localized production. Mexico and Canada, with their established medical device clusters, are well-positioned to support these changes if manufacturers invest in flexible capacity. Regional trade agreements that facilitate cross-border movement of components and finished goods will become increasingly important.

3. Supply Chain Pressures and Tariffs Drive Manufacturing Realignment

Tariff exposure, geopolitical risk, and fluctuating material costs are prompting medtech companies to diversify sourcing and adopt multi-region manufacturing footprints. The trend toward nearshoring, already evident in other sectors, is gaining momentum in medtech as firms seek to reduce supply chain fragility and shorten lead times.

Why it matters for North America: The region stands to benefit from this shift. Mexico’s proximity to the U.S. market, combined with USMCA tariff preferences, makes it an attractive destination for medtech assembly and distribution. Canada offers strengths in advanced materials and specialty manufacturing. U.S. industrial policy, including incentives for semiconductor and pharmaceutical production, could extend to medical devices, further anchoring the supply chain within North America. Companies that strategically rebalance production across the three countries can enhance resilience while maintaining export competitiveness.

4. GLP-1 Therapies Alter Care Pathways and Device Demand

The rapid adoption of GLP-1 receptor agonists for weight management and metabolic disorders is reshaping clinical pathways with ripple effects across multiple device markets. Bariatric surgery volumes are under pressure in certain segments, while diabetes care, cardiovascular monitoring, and sleep apnea management are experiencing evolving demand patterns.

Why it matters for North America: As procedure volumes shift, manufacturers must adjust production forecasts and R&D portfolios. The GLP-1 effect is not uniform: some device categories may see declining utilization, while others gain. For North American medtech companies, this underscores the need for flexible manufacturing, agile supply chains, and regional market intelligence. It also highlights opportunities in digital health tools that support medication adherence, remote monitoring, and patient engagement.

5. Platform-Based Competition and the Rise of Enabling Technologies

Robotics, imaging, navigation, and digital workflow software are converging into integrated platforms that anchor entire service lines. This shift from standalone products to ecosystems is transforming competitive dynamics, as companies invest heavily in AI-enabled technologies to differentiate themselves. Emerging open-platform systems are also creating new opportunities for third-party developers and data-driven services.

Why it matters for North America: The platform shift has significant implications for industrial policy and workforce development. Advanced manufacturing in medtech now requires software engineering, data science, and systems integration capabilities. North America’s technology ecosystem, particularly in the United States, is well-positioned to lead in this arena. Cross-border collaboration between U.S. tech hubs, Mexican manufacturing centers, and Canadian AI research clusters could accelerate innovation and create high-value jobs across the region.

Trade Impact

The medtech trends outlined above will have a profound impact on North American trade flows. Supply chain realignment could increase intra-regional trade in medical devices and components as manufacturers shift production from Asia to Mexico and Canada. Tariff-driven cost pressures may prompt firms to qualify new suppliers, potentially boosting trade in specialized materials and subassemblies.

At the same time, pricing reforms in China and other markets could lead North American exporters to seek new demand in Latin America and Europe, diversifying export destinations. The shift to platform-based products may also alter the composition of trade, with software and digital services accompanying physical devices.

USMCA rules of origin and regulatory cooperation will be tested as companies optimize regional supply chains. Smooth customs procedures, mutual recognition of certifications, and alignment on digital trade rules will be critical to ensuring that North America remains an integrated, competitive production base.

Regional Perspective

• United States: The U.S. continues to drive innovation and set regulatory standards. Tariffs and industrial policy are encouraging domestic manufacturing, but there is a growing reliance on Mexico as an export platform. The shift to outpatient care and platform ecosystems will create demand for high-skilled workers and advanced digital infrastructure.
• Canada: Canada’s strengths in AI, materials science, and specialized medical technologies position it as a partner in platform development and advanced components. The country’s trade agreements with both the U.S. and Mexico provide stable access to regional markets.
• Mexico: Mexico’s medtech manufacturing sector is poised to benefit from nearshoring trends. With a well-established base of medical device plants, particularly in Tijuana and Juárez, Mexico can capture increased assembly and logistics activities. However, infrastructure bottlenecks and energy reliability need addressing to fully realize this potential.
• USMCA: The trade agreement provides the institutional framework for regional integration. As medtech supply chains become more intricate, USMCA mechanisms for resolving disputes and harmonizing standards will grow in importance.

Future Outlook

Over the next three to five years, North American medtech manufacturing is expected to become more geographically diversified and technologically advanced. Key developments to watch include:

• Nearshoring acceleration: Continued tariff pressures and geopolitical uncertainty will drive further relocation of medical device production to Mexico, with Canada playing a supporting role in niche areas.
• AI integration: Artificial intelligence will become embedded in medical devices and manufacturing processes, improving quality control, predictive maintenance, and supply chain visibility. Regional data-sharing frameworks will be crucial.
• Infrastructure investment: Modernized highways, border crossings, and energy grids will be essential to support the seamless movement of goods. Public-private partnerships could play a significant role.
• Clustering and specialization: Industrial clusters will form around emerging technologies, with the U.S. focusing on innovation and digital platforms, Mexico on high-volume manufacturing, and Canada on select advanced technologies.
• Workforce development: A joint approach to workforce training in automation, data science, and medtech-specific skills will be necessary to maintain competitiveness.

Conclusion

The medtech trends identified by Clarivate are not just global industry shifts; they are strategic forces that will shape North American manufacturing and trade architecture. Companies that align their supply chain, product, and investment strategies with these dynamics will be better positioned to thrive. Policymakers, meanwhile, have an opportunity to strengthen regional competitiveness through coordinated infrastructure spending, trade facilitation, and innovation support.

North America’s future in medtech hinges on its ability to integrate manufacturing with digital intelligence, leverage nearshoring advantages, and deepen cross-border collaboration. The groundwork laid today will determine whether the region continues to lead in this critical sector.